1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
UCB S.A.

UCB S.A.

UCBJY
UCB S.A.US flagOther OTC
144.63
USD
-1.70
- -
55.06BMarket Cap
UCB S.A.
UCBJY
(Other OTC)

Recent

price

144.63

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
17.86
18.19
19.31
17.19
17.56
20.18
22.02
24.06
24.58
26.24
14.14
15.29
14.55
13.84
16.19
- -
Revenue per Share
0.58
1.33
1.39
0.88
1.1
3.24
2.76
4
4.24
4.23
1.94
2.8
1.1
0.9
2.8
- -
Basic EPS, GAAP
2.38
0.87
0.75
-0.31
2.05
0.52
1.53
3.81
3.97
3.14
1.94
2.8
1.97
1.17
2.42
- -
Free Cash Flow per Basic Share
0.97
0.99
1.12
1.13
1.17
1.17
1.23
1.15
1.18
1.22
0.62
0.64
0.65
0.66
0.68
- -
Dividend per Share
- -
14.65
14.85
13.77
13.21
15.18
17.32
20.24
23.31
26.51
15.99
16.65
16.99
17.34
19.46
- -
Book Value per Share
-9.81
-9.09
-9.5
-9.24
-6.61
-3.5
-3.06
0.43
2.2
5.93
-1.76
0.14
-2.88
-1.35
1.28
- -
Tangible Book Value per Share
180
178
179
182
190
192
188
188
188
187
378
378
379
379
380
- -
Basic Weighted Avg Shares
3,218
3,246
3,462
3,132
3,344
3,876
4,147
4,530
4,632
4,913
5,347
5,777
5,517
5,252
6,152
7,741
Sales/Revenue/Turnover
14.51
13.52
13.72
10.95
12.23
18.5
23.37
24.57
22.82
21.49
19.45
22.88
12.71
12.05
13.75
25.89
Operating Margin (%)
255
246
230
238
220
250
232
234
288
313
354
323
589
691
641
627
Depreciation Expense
104
238
249
160
209
623
520
753
800
792
732
1,058
418
343
1,065
1,558
Net Income, GAAP
- -
3.86
13.31
44.63
5.41
26.06
26.05
22.06
19.7
15.21
13.52
13.87
17.81
22.22
8.43
14.49
Effective Tax Rate (%)
3.23
7.33
7.19
5.11
6.25
16.07
12.54
16.62
17.27
16.12
13.69
18.31
7.58
6.53
17.31
20.13
Profit Margin (%)
-122
94
14
79
-104
-223
-87
728
798
901
768
886
192
828
1,259
1,653
Working Capital
1,758
1,772
1,890
2,027
1,747
1,585
1,574
1,534
1,350
975
2,316
2,068
2,638
2,996
2,963
2,183
LT Debt
4,592
4,701
4,593
4,322
4,842
5,546
5,477
5,736
6,255
7,009
7,272
8,386
9,064
8,975
10,029
10,867
Total Equity
- -
6.26
6.14
2.71
5.28
6.71
9.04
11.61
11.09
11.03
9.72
11.02
5.11
4.09
6.13
12.94
Return on Invested Capital (%)
- -
11.31
8.22
5.3
7.42
13.42
11.53
15.47
14.84
13.57
10.15
12.74
5.36
4.8
12.08
15.62
Return on Capital (%)
7.91
18.2
9.44
6.19
8.32
22.95
16.83
21.29
19.5
16.93
13.3
17.15
6.56
5.27
15.24
19.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.09%
8.5%
8.36%
Free Cash Flow
52.66%
36.37%
100.22%
Net Income, GAAP
24.88%
44.58%
46.29%
Sales/Revenue/Turnover
7.51%
8.34%
25.83%
Total Cash Common Dividend
1.65%
2.36%
1.93%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5,252
2024
- -
- -
- -
- -
6,152
2025
- -
- -
- -
- -
7,741

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.9
2024
- -
- -
- -
- -
2.8
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.66
2024
- -
- -
- -
- -
0.68
2025
- -
- -
- -
- -
- -
Similar Companies
NewAmsterdam Pharma Company N.V. (NAMS)
Veru Inc. (VERU)
Neuren Pharmaceuticals Limited (NEU.AX)
NetScientific plc (NSCI.L)
Agentix Corp. (AGTX)
ArriVent BioPharma, Inc. (AVBP)
Business
UCB SA (UCB.BR; UCBJY) is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines and solutions for severe diseases in neurology and immunology, targeting patients with central nervous system disorders and autoimmune conditions worldwide. Founded in 1928 by Emmanuel Janssen and headquartered in Brussels, Belgium, the company employs over 9,000 people across nearly 40 countries, including major operations in the U.S., Europe, Japan, and China; it offers key products such as BIMZELX (bimekizumab) for psoriasis, hidradenitis suppurativa, and other inflammatory conditions; RYSTIGGO (rozanolixizumab-noli) and ZILBRYSQ (zilucoplan) for generalized myasthenia gravis; FINTEPLA (fenfluramine) for seizures in rare epilepsies; EVENITY (romosozumab) for osteoporosis; BRIVIACT (brivaracetam), KEPPRA (levetiracetam), and VIMPAT (lacosamide) for epilepsy; CIMZIA (certolizumab pegol) for rheumatoid arthritis, psoriatic arthritis, and Crohn's disease; NEUPRO (rotigotine) for Parkinson's disease and restless legs syndrome; and established brands including legacy antihistamines and others undergoing portfolio simplification. UCB generates revenue from these immunology and neurology portfolios, with 2024 sales reaching €6.1 billion and 2025 guidance upgraded to exceed €7.6 billion (24% growth) driven by strong demand for its five growth drivers; recent developments include the November 2024 sale of its mature neurology and allergy business in China to CBC Group and Mubadala for $680 million, forming NeuroGen Pharma; a November 2024 licensing agreement with Bioray for BIMZELX commercialization in China; a June 2025 announcement of a $5 billion U.S. biologics manufacturing facility investment expected to create 300 permanent high-skilled jobs and over 500 construction roles while enhancing supply chain resilience; ongoing global launches and expansions for RYSTIGGO (U.S. 2023, Japan/Europe 2023-2024), ZILBRYSQ, and FINTEPLA; and sustained R&D investment representing about a quarter of revenue into pipeline advancements across neurology, immunology, and rare diseases.

Company News

APIChatGPT

  • seekingalpha.com

    UCB SA (UCBJY) Analyst/Investor Day Transcript

  • zacks.com

    UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know

  • reuters.com

    Belgium's UCB in autoimmune drug deal with Antengene

  • seekingalpha.com

    UCB SA (UCBJY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

  • defenseworld.net

    Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis

  • defenseworld.net

    UCB (OTCMKTS:UCBJY) Share Price Crosses Above 50 Day Moving Average – What’s Next?

  • zacks.com

    Recent Price Trend in UCB (UCBJY) is Your Friend, Here's Why

  • zacks.com

    UCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why

  • zacks.com

    All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy